News
-
Janssen Announces Initiation Of Phase 3 Development Program For Sirukumab In Rheumatoid Arthritis
8/23/2012
Janssen Biologics (Ireland) announced today it has initiated the Phase 3 development program for sirukumab (CNTO 136) as part of a collaboration with GlaxoSmithKline plc (GSK).
-
AbGenomics International Obtains FDA Agreement On Its Phase 2 Clinical Trial Plans
8/17/2012
Los Altos, CA /PRNewswire-iReach/ - AbGenomics International announced today that it has obtained agreement from U.S. Food and Drug Administration (FDA) for its proposed plans for a phase 2 clinical trial of the novel autoimmune therapeutic candidate, AbGn-168H.
-
Amgen Announces Termination Of Ganitumab Phase 3 Study For Futility In Metastatic Pancreatic Cancer
8/8/2012
Amgen (NASDAQ: AMGN) today announced a decision to stop the ganitumab (AMG 479) Phase 3 GAMMA (Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas) trial following the recommendation of an independent Data Monitoring Committee (DMC) overseeing the trial.
-
TiGenix Completes Patient Enrollment In Phase IIa Rheumatoid Arthritis Study
8/8/2012
TiGenix (EURONEXT BRUSSELS: TIG), the European leader in cell therapy, announced today the completion of patient enrollment in the Company's Phase IIa study of Cx611, a suspension of expanded allogeneic adult stem cells, in rheumatoid arthritis.
-
Ampio Advances NCE001 Cancer Drug Into Preclinical Development Following Successful Recent Financing And The Granting Of Patents In USA, Canada, Europe And China
7/16/2012
Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE), a biopharmaceutical company developing repurposed drugs and new molecular entities (NMEs) that treat inflammatory diseases, including osteoarthritis, diabetic macular edema (DME) and sexual dysfunction and conducting clinical trials on its four lead drugs (Ampion™, Optina™, Zertane™ & Zertane-ED™) announced today the advancement of NCE001, from its proprietary methylphenidate derivatives family of compounds, to preclinical development for the treatment of glioblastoma multiforme, renal cell carcinoma and inflammatory breast cancer following the granting of multiple composition of matter and use patents in the USA, Canada, Europe and China.
-
AstraZeneca And Amgen Announce Collaboration To Jointly Develop And Commercialise Clinical-Stage Inflammation Portfolio
4/4/2012
AstraZeneca and Amgen recently announced an agreement to jointly develop and commercialise five monoclonal antibodies from Amgen’s clinical inflammation portfolio: AMG 139, AMG 157, AMG 181, AMG 557 and brodalumab (AMG 827).
-
Lilly's Anti-IL-17 Monoclonal Antibody, Ixekizumab, Met Primary Endpoint In Phase II Study In Patients With Chronic Plaque Psoriasis
3/29/2012
New Phase II data, published today in the New England Journal of Medicine, showed that Eli Lilly and Company's (NYSE: LLY) ixekizumab (pronounced ix" e kiz' ue mab, previously known as LY2439821), an anti-IL-17 monoclonal antibody, met its primary endpoint in patients with moderate-to-severe plaque psoriasis, with significantly more patients achieving at least a 75 percent improvement in Psoriasis Area and Severity Index (PASI) scores from baseline (PASI 75) compared with placebo at week 12.
-
Amgen's PCSK9 Inhibitor Reduced LDL Cholesterol Up To 81 Percent In Phase 1b Study
3/26/2012
Amgen (NASDAQ: AMGN) announced today positive results from a Phase 1b clinical study of AMG 145, an investigational PCSK9 inhibitor, in patients with high cholesterol who were taking statins.
-
Premier Research Expands Salt Lake City And Phoenix Testing Facilities Adding 50% Capacity
2/22/2012
Premier Research Group Limited announces the opening of new state-of-the-art clinical research facilities located in Phoenix and Salt Lake City, increasing their testing facilities capacity by 50%.
-
Nano-Sized Protein Clusters Address Major Challenge Of Drug Delivery
2/21/2012
A new form of proteins discovered by researchers at The University of Texas at Austin could drastically improve treatments for cancer and other diseases, as well as overcome some of the largest challenges in therapeutics: delivering drugs to patients safely, easily and more effectively.